Literature DB >> 29773598

Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA.

Feng-Ming Tien1,2,3, Hsin-An Hou4, Jih-Luh Tang1,3, Yuan-Yeh Kuo5, Chien-Yuan Chen1, Cheng-Hong Tsai1,3, Ming Yao1, Chien-Ting Lin1,3, Chi-Cheng Li1,3, Shang-Yi Huang1, Bor-Sheng Ko1, Szu-Chun Hsu6, Shang-Ju Wu1, Jia-Hau Liu1,3, Sheng Chieh Chou1, Woei Tsay1, Mei-Hsuan Tseng1, Ming-Chih Liu7, Chia-Wen Liu7, Liang-In Lin8, Wen-Chien Chou1,6, Hwei-Fang Tien4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29773598      PMCID： PMC6278974          DOI： 10.3324/haematol.2018.189043

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.

Authors:  Hsin-An Hou; Tai-Chung Huang; Liang-In Lin; Chieh-Yu Liu; Chien-Yuan Chen; Wen-Chien Chou; Jih-Luh Tang; Mei-Hsuan Tseng; Chi-Fei Huang; Ying-Chieh Chiang; Fen-Yu Lee; Ming-Chih Liu; Ming Yao; Shang-Yi Huang; Bor-Sheng Ko; Szu-Chun Hsu; Shang-Ju Wu; Woei Tsay; Yao-Chang Chen; Hwei-Fang Tien
Journal:  Blood       Date:  2010-04-05       Impact factor: 22.113

2.  The role of different genetic subtypes of CEBPA mutated AML.

Authors:  A Fasan; C Haferlach; T Alpermann; S Jeromin; V Grossmann; C Eder; S Weissmann; F Dicker; A Kohlmann; S Schindela; W Kern; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2013-09-23       Impact factor: 11.528

3.  Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Authors:  Erdogan Taskesen; Lars Bullinger; Andrea Corbacioglu; Mathijs A Sanders; Claudia A J Erpelinck; Bas J Wouters; Sonja C van der Poel-van de Luytgaarde; Frederik Damm; Jürgen Krauter; Arnold Ganser; Richard F Schlenk; Bob Löwenberg; Ruud Delwel; Hartmut Döhner; Peter J M Valk; Konstanze Döhner
Journal:  Blood       Date:  2010-12-21       Impact factor: 22.113

4.  TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.

Authors:  Wen-Chien Chou; Sheng-Chieh Chou; Chieh-Yu Liu; Chien-Yuan Chen; Hsin-An Hou; Yuan-Yeh Kuo; Ming-Cheng Lee; Bor-Sheng Ko; Jih-Luh Tang; Ming Yao; Woei Tsay; Shang-Ju Wu; Shang-Yi Huang; Szu-Chun Hsu; Yao-Chang Chen; Yi-Chang Chang; Yi-Yi Kuo; Kuan-Ting Kuo; Fen-Yu Lee; Ming-Chi Liu; Chia-Wen Liu; Mei-Hsuan Tseng; Chi-Fei Huang; Hwei-Fang Tien
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

5.  CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.

Authors:  Vera Grossmann; Claudia Haferlach; Niroshan Nadarajah; Annette Fasan; Sandra Weissmann; Andreas Roller; Christiane Eder; Elisa Stopp; Wolfgang Kern; Torsten Haferlach; Alexander Kohlmann; Susanne Schnittger
Journal:  Br J Haematol       Date:  2013-03-25       Impact factor: 6.998

6.  The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.

Authors:  Richard F Schlenk; Erdogan Taskesen; Yvette van Norden; Jürgen Krauter; Arnold Ganser; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Andrea Corbacioglu; Gudrun Göhring; Andrea Kündgen; Gerhard Held; Katharina Götze; Edo Vellenga; Juergen Kuball; Urs Schanz; Jakob Passweg; Thomas Pabst; Johan Maertens; Gert J Ossenkoppele; Ruud Delwel; Hartmut Döhner; Jan J Cornelissen; Konstanze Döhner; Bob Löwenberg
Journal:  Blood       Date:  2013-07-17       Impact factor: 22.113

7.  Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.

Authors:  Vincent-Philippe Lavallée; Jana Krosl; Sébastien Lemieux; Geneviève Boucher; Patrick Gendron; Caroline Pabst; Isabel Boivin; Anne Marinier; Cynthia J Guidos; Sylvain Meloche; Josée Hébert; Guy Sauvageau
Journal:  Blood       Date:  2016-03-31       Impact factor: 22.113

8.  Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.

Authors:  Jae-Sook Ahn; Jae-Young Kim; Hyeoung-Joon Kim; Yeo-Kyeoung Kim; Seung-Shin Lee; Sung-Hoon Jung; Deok-Hwan Yang; Je-Jung Lee; Nan Young Kim; Seung Hyun Choi; Mark D Minden; Chul Won Jung; Jun-Ho Jang; Hee Je Kim; Joon Ho Moon; Sang Kyun Sohn; Jong-Ho Won; Sung-Hyun Kim; Dennis Dong Hwan Kim
Journal:  Ann Hematol       Date:  2015-11-04       Impact factor: 3.673

9.  Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

Authors:  Annika Dufour; Friederike Schneider; Klaus H Metzeler; Eva Hoster; Stephanie Schneider; Evelyn Zellmeier; Tobias Benthaus; Maria-Cristina Sauerland; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Jan Braess; Wolfgang Hiddemann; Stefan K Bohlander; Karsten Spiekermann
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544

10.  Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia.

Authors:  Hsin-An Hou; Chieh-Yu Liu; Yuan-Yeh Kuo; Wen-Chien Chou; Cheng-Hong Tsai; Chien-Chin Lin; Liang-In Lin; Mei-Hsuan Tseng; Ying-Chieh Chiang; Ming-Chih Liu; Chia-Wen Liu; Jih-Luh Tang; Ming Yao; Chi-Cheng Li; Shang-Yi Huang; Bor-Sheng Ko; Szu-Chun Hsu; Chien-Yuan Chen; Chien-Ting Lin; Shang-Ju Wu; Woei Tsay; Hwei-Fang Tien
Journal:  Oncotarget       Date:  2016-02-23
View more
  8 in total

1.  Relapse of acute myeloid leukemia after allogeneic stem cell transplantation is associated with gain of WT1 alterations and high mutation load.

Authors:  Sebastian Vosberg; Luise Hartmann; Klaus H Metzeler; Nikola P Konstandin; Stephanie Schneider; Ashok Varadharajan; Andreas Hauser; Stefan Krebs; Helmut Blum; Stefan K Bohlander; Wolfgang Hiddemann; Johanna Tischer; Karsten Spiekermann; Philipp A Greif
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941

Review 2.  Zebrafish models of acute leukemias: Current models and future directions.

Authors:  Brandon Molina; Jasmine Chavez; Stephanie Grainger
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2020-12-19       Impact factor: 5.814

3.  Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.

Authors:  Satoshi Wakita; Masahiro Sakaguchi; Iekuni Oh; Shinichi Kako; Takashi Toya; Yuho Najima; Noriko Doki; Junya Kanda; Junya Kuroda; Shinichiro Mori; Atsushi Satake; Kensuke Usuki; Toshimitsu Ueki; Nobuhiko Uoshima; Yutaka Kobayashi; Eri Kawata; Kenji Tajika; Yuhei Nagao; Katsuhiro Shono; Motoharu Shibusawa; Jiro Tadokoro; Kensuke Kayamori; Masao Hagihara; Hitoji Uchiyama; Naoyuki Uchida; Yasushi Kubota; Shinya Kimura; Hisao Nagoshi; Tatsuo Ichinohe; Saiko Kurosawa; Sayuri Motomura; Akiko Hashimoto; Hideharu Muto; Eriko Sato; Masao Ogata; Kenjiro Mitsuhashi; Jun Ando; Atsushi Marumo; Ikuko Omori; Yusuke Fujiwara; Kazuki Terada; Shunsuke Yui; Kunihito Arai; Tomoaki Kitano; Miho Miyata; Akiyo Kurosawa; Ayumi Mizoguchi; Norio Komatsu; Takahiro Fukuda; Kazuteru Ohashi; Yoshinobu Kanda; Koiti Inokuchi; Hiroki Yamaguchi
Journal:  Blood Adv       Date:  2022-01-11

4.  Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic CEBPA Mutations Based on a Multi-Gene Panel and Nomogram Model.

Authors:  Li-Xin Wu; Hao Jiang; Ying-Jun Chang; Ya-Lan Zhou; Jing Wang; Zi-Long Wang; Lei-Ming Cao; Jin-Lan Li; Qiu-Yu Sun; Shan-Bo Cao; Feng Lou; Tao Zhou; Li-Xia Liu; Cheng-Cheng Wang; Yu Wang; Qian Jiang; Lan-Ping Xu; Xiao-Hui Zhang; Kai-Yan Liu; Xiao-Jun Huang; Guo-Rui Ruan
Journal:  Front Oncol       Date:  2021-08-17       Impact factor: 6.244

5.  A systematic analysis of genetic interactions and their underlying biology in childhood cancer.

Authors:  Josephine T Daub; Saman Amini; Denise J E Kersjes; Xiaotu Ma; Natalie Jäger; Jinghui Zhang; Stefan M Pfister; Frank C P Holstege; Patrick Kemmeren
Journal:  Commun Biol       Date:  2021-10-06

Review 6.  Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions.

Authors:  Long Su; Yuan-Yuan Shi; Zeng-Yan Liu; Su-Jun Gao
Journal:  Front Oncol       Date:  2022-02-01       Impact factor: 6.244

7.  What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort.

Authors:  Morten Krogh Herlin; Sara A Yones; Eigil Kjeldsen; Linda Holmfeldt; Henrik Hasle
Journal:  Genes (Basel)       Date:  2021-05-21       Impact factor: 4.096

Review 8.  Treatment of Acute Myeloid Leukemia in the Era of Genomics-Achievements and Persisting Challenges.

Authors:  Steven D Green; Heiko Konig
Journal:  Front Genet       Date:  2020-05-27       Impact factor: 4.599
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.